ORIENT-11

NCT03607539 📎

Regimen

Experimental
sintilimab + pemetrexed + platinum
Control
placebo + pemetrexed + platinum

Population

Chinese 1L non-sq NSCLC EGFR/ALK-WT

Key finding

mPFS 8.9 vs 5.0 mo, HR 0.482 (0.362-0.643); Chinese-developed PD-1 1L data

Source: PMID 32781208

Timeline

  • Enrollment start: 2018-08-23 📎

Guideline citations

  • CSCO NSCLC 2025 ⚠️ OCR source